Physician profile
Brad D Lerner
NPI 1558346809
$20,184.12
in general payments reported to CMS, 2019-2025
58 companies · $2,222 in 2025
The $2,222 reported for 2025 was more than what 82% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,606 · 2020: $2,247 · 2021: $2,067 · 2022: $3,130 · 2023: $4,702 · 2024: $2,210 · 2025: $2,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,246 · Travel and Lodging: $1,676 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,245.89 |
| Travel and Lodging | $1,676.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $111.79 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sn Holdings, LLC | $3,892.13 | 2022-2023 | |
| Boston Scientific Corporation | $2,639.54 | 2019-2024 | Spaceoar Vue System - 10ml |
| Janssen Biotech, INC. | $1,877.24 | 2019-2025 | Erleada, Akeega |
| Urogpo LLC | $1,271.67 | 2019 | |
| Teleflex LLC | $1,037.11 | 2021-2025 | Urolift, Barrigel |
| Astellas Pharma US INC | $997.88 | 2019-2024 | Myrbetriq, Xtandi |
| Sumitomo Pharma America, INC. | $938.27 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $778.07 | 2019-2025 | |
| Medtronic, INC. | $623.85 | 2022-2025 | Interstim, Intellis Adaptivestim, Altaviva |
| Dendreon Pharmaceuticals LLC | $577.07 | 2019-2025 | Provenge |
| Endo Pharmaceuticals INC. | $505.26 | 2019-2024 | Aveed, Xiaflex |
| Abbvie INC. | $434.12 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $370.08 | 2019-2025 | |
| Progenics Pharmaceuticals, INC. | $352.40 | 2022-2025 | Pylarify |
| Ferring Pharmaceuticals INC. | $345.51 | 2019-2025 | Adstiladrin |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$361,837.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Lerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.